ReviewCurrent opinion in immunology2008
Peptide epitope identification for tumor-reactive CD4 T cells.
Review in Current opinion in immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.Molecular therapy. Oncology · 2025Article
- Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.Journal for immunotherapy of cancer · 2020Article
- Distinct prognostic value of circulating anti-telomerase CD4British journal of cancer · 2019Article
- Cancer immunotherapy: moving forward with peptide T cell vaccines.Current opinion in immunology · 2017Review
- Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.Cancer immunology research · 2017Article
- EBP1 protein modulates the expression of human MHC class II molecules in non-hematopoietic cancer cells.International journal of oncology · 2015Article
- Review
- EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.British journal of cancer · 2013Article
- Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.Human vaccines & immunotherapeutics · 2013Review
- Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination.Oncoimmunology · 2013Article
- Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration.ISRN oncology · 2013Article
- A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope.Cancer immunology, immunotherapy : CII · 2012Article
- First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.Cancer science · 2012Article
- Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.Journal of translational medicine · 2011Article
- Characterization of human CD4 helper T cell responses against Aurora kinase A.Cancer immunology, immunotherapy : CII · 2010Article
- Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.Cancer immunology, immunotherapy : CII · 2010Article
- Focal adhesion kinase as an immunotherapeutic target.Cancer immunology, immunotherapy : CII · 2009Article
- Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells.Cancer science · 2009Article
- Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.British journal of cancer · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.